

Media Release

Zug, 1 April 2015

Net asset value (NAV) per share of CHF 140.60 as at 31 March 2015

HBM Healthcare Investments once again reported very pleasing value growth for its 2014/2015 business year. Factoring in the cash dividend of CHF 3 per share, net asset value (NAV) per share rose by 32 percent to CHF 140.60 as at 31 March 2015. The share price climbed by 47 percent to CHF 108.00 during the same period.

Based on its net asset value as at 31 March 2015, HBM Healthcare Investments is expecting a consolidated net profit in excess of CHF 255 million for the 2014/2015 financial year just ended. In the previous year, the Company recorded a consolidated net profit of CHF 353.5 million.

In addition to the major holdings in PTC Therapeutics (book profit CHF +59 million / share price up +133% in investment currency in FY 14/15), Pacira Pharmaceuticals (CHF +38 million / +27%), Skyepharma (CHF +34 million / +28%), Ophthotech Corporation (CHF +25 million / +30%) and Basilea Pharmaceutica (CHF +9 million / +10%), most of which originate from the portfolio of private companies, the IPOs of Paratek Pharmaceuticals (CHF +40 million / +263%) and Forward Pharma (held via the Nordic Biotech Fund, CHF +40 million / fund valuation up +1060%) released further previously unrecognised value, and were a major factor in the good result for the year. Other significant contributors to results were the new and expanded holdings in public companies Esperion Therapeutics (CHF +32 million / +519%), Receptos (CHF +16 million / +293%), Genmab (CHF +11 million / +132%) and Collectis (CHF +8 million / +402%). These are all developing innovative new therapies with major market potential, and have presented very convincing clinical data.

The total increase in value over the past three financial years amounts to CHF 678 million, net of all costs. Factoring in the cumulated cash dividends to shareholders of CHF 36 million and share buy-backs of CHF 114 million, the Company's net assets expanded from CHF 546 million to CHF 1.074 billion during this period.

These results are unaudited figures, based on the current status of work on the closing of the annual financial statements. The final annual result will be published on 13 May 2015.

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA

HBM Healthcare Investments

For further information, please contact Dr. Andreas Wicki, tel.: +41 41 768 11 08, andreas.wicki@hbmhealthcare.com

Information on HBM Healthcare Investments Ltd

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of some 25 promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM Healthcare Investments Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM Healthcare Investments Ltd

Bundesplatz 1 CH-6300 Zug | Tel: +41 41 768 11 08 | Fax: +41 41 768 11 09 | info@hbmhealthcare.com
www.hbmhealthcare.com